Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer

The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability...

Full description

Bibliographic Details
Main Authors: Wout Devlies, Markus Eckstein, Alessia Cimadamore, Gaëtan Devos, Lisa Moris, Thomas Van den Broeck, Rodolfo Montironi, Steven Joniau, Frank Claessens, Thomas Gevaert
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cells
Subjects:
prostate cancer
biomarker
targeted therapies
histology
mCRPC
androgen receptor
Online Access:https://www.mdpi.com/2073-4409/9/11/2494
Description
Summary:The development of targeted therapies increases treatment options for metastatic castration resistant prostate cancer (mCRPC) patients. There is a need for strong predictive and prognostic signatures to guide physicians in treating mCRPC patients. In this review we unravel the possible actionability in the AR pathway, PI3K AKT signaling, and DNA repair pathways. Additionally, we make recommendations on biomarker trial design, and the clinical use of this new type of data.
ISSN:2073-4409

Similar Items